Mesoblast (MESO) EBIT Growth (3y) (2017 - 2023)

Mesoblast (MESO) EBIT Growth (3y) (2017 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 8.36%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 89.72%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 44.54%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -26.00%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -18.82%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 44.34%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 81.27%
10 Mesoblast 2.01 Bn 1.87 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 -1.01%
Mar 31, 2023 39.57%
Dec 31, 2022 15.82%
Sep 30, 2022 -47.77%
Jun 30, 2022 26.07%
Mar 31, 2022 29.57%
Dec 31, 2021 -1.59%
Sep 30, 2021 6.70%
Jun 30, 2021 8.10%
Mar 31, 2021 3.20%
Dec 31, 2020 -30.91%
Sep 30, 2020 -29.11%
Jun 30, 2020 18.40%
Mar 31, 2020 1.57%
Dec 31, 2019 -2.23%
Sep 30, 2019 43.70%
Jun 30, 2019 4.83%
Mar 31, 2019 -0.59%
Dec 31, 2018 -7.15%
Jun 30, 2018 10.36%